KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Non-Current Debt (2018 - 2021)

Historic Non-Current Debt for TherapeuticsMD (TXMD) over the last 6 years, with Q3 2021 value amounting to $171.7 million.

  • TherapeuticsMD's Non-Current Debt fell 2755.24% to $171.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $171.7 million, marking a year-over-year decrease of 2755.24%. This contributed to the annual value of $237.7 million for FY2020, which is 2212.52% up from last year.
  • Per TherapeuticsMD's latest filing, its Non-Current Debt stood at $171.7 million for Q3 2021, which was down 2755.24% from $175.3 million recorded in Q2 2021.
  • In the past 5 years, TherapeuticsMD's Non-Current Debt ranged from a high of $243.4 million in Q1 2020 and a low of $73.1 million during Q2 2018
  • Moreover, its 4-year median value for Non-Current Debt was $179.0 million (2021), whereas its average is $163.1 million.
  • As far as peak fluctuations go, TherapeuticsMD's Non-Current Debt skyrocketed by 23119.02% in 2020, and later plummeted by 2755.24% in 2021.
  • Quarter analysis of 4 years shows TherapeuticsMD's Non-Current Debt stood at $73.4 million in 2018, then skyrocketed by 165.24% to $194.6 million in 2019, then grew by 22.13% to $237.7 million in 2020, then fell by 27.75% to $171.7 million in 2021.
  • Its Non-Current Debt stands at $171.7 million for Q3 2021, versus $175.3 million for Q2 2021 and $179.0 million for Q1 2021.